Mirum Pharmaceuticals Inc · Q1 2023 earnings

Briefing

Mirum Pharmaceuticals' Q1 2023 financial performance was reported, featuring revenue growth and advancements in LIVMARLI's commercialization and label expansion.

Mirum Pharmaceuticals reported a strong start to 2023, with total revenue of $31.6 million, including $29.1 million in net product sales for LIVMARLI. The company is progressing with the global commercial launch of LIVMARLI, label expansions, and pipeline milestones.

• Total revenue reached $31.6 million, including $29.1 million from LIVMARLI net product sales.
• LIVMARLI's U.S. label was expanded to include infants three months of age and older for Alagille syndrome.
• Regulatory submissions for LIVMARLI in PFIC are under review in the U.S. and Europe.
• Three data catalysts are expected in the second half of 2023 for LIVMARLI in biliary atresia and volixibat in primary sclerosing cholangitis and primary biliary cholangitis.

Headline financials

Revenue & EPS history

Mirum Pharmaceuticals is focused on continued commercial success for LIVMARLI, including growth in year-over-year net product sales, LIVMARLI label expansion in the U.S. and Europe, the results, conduct and progress of Mirum’s ongoing and planned studies for its product candidates, including the receipt and timing of planned data readouts, the delivery of LIVMARLI to more patients, and the regulatory approval path for its product candidates globally.